Adalvo announces the first-to-market launch of Pregabalin ER (Extended Release) tablets in Poland, in partnership with Exeltis.
With this launch, Adalvo further strengthens its position as the first and only supplier of Pregabalin ER in Europe, following successful entries in several key EU markets. This achievement highlights Adalvo’s leadership in bringing differentiated products to market under challenging regulatory and IP conditions.
Pregabalin ER is used in the treatment of neuropathic pain and represents an important advancement in patient-centric therapy, offering the convenience of once-daily dosing.
The European market for Pregabalin products reached $753 million in sales in 2024 (IQVIA), reflecting strong demand for effective neuropathic pain treatments.
Adalvo continues to expand access to complex generics and value-added medicines across regulated markets, with additional EU launches to follow.
Partner up now to access opportunities across Adalvo’s high-impact portfolio.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 19 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.
The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Exeltis
Exeltis is a fast-growing division of the integrated health sciences group Insud Pharma. It boasts a strong position in the Women’s Health and Central Nervous System (CNS) segments, and is constantly innovating and seeking new treatments to improve health and wellbeing around the world. With a global footprint spanning over 50 countries, Exeltis has a team of more than 4,000 professionals supported by a global manufacturing network.
Exeltis is part of Insud Pharma, a pharmaceutical group with more than 45 years of history, 9,000 employees worldwide and 20 manufacturing plants.
Insud Pharma operates throughout the value chain of the pharmaceutical industry, offering specialized knowledge in scientific research, development, manufacturing, sale and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and pharmaceutical products of brand and biopharmaceuticals.
Disclaimer: The decision may be subject to appeal. Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.